Summary:
CNS Network is conducting a Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Qualified Participants Must:
• Be between 18 and 85 years (inclusive)
•
Have a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C
Qualified Participants May Receive:
study-related medical care and investigational medication at no cost and may be compensated for time and travel.